SCHEMBL10028705

SCHEMBL10028705

N=C(NCCCCc1ccc(O)cc1)NC(=O)c1nc(Cl)c(N)nc1N

nearest known ligand 0.65

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SCNN1A P37088 20/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028706 0.99 SCNN1A (0.66) SCNN1A
SCHEMBL14180722 0.97 SCNN1A (0.64) SCNN1A
SCHEMBL9913772 0.93 SCNN1A (0.64) SCNN1A
SCHEMBL9913768 0.92 SCNN1A (0.65) SCNN1A
SCHEMBL9913777 0.92 SCNN1A (0.57) SCNN1A
SCHEMBL707971 0.91 SCNN1A (0.55) SCNN1A
SCHEMBL16808735 0.91 SCNN1A (0.54) SCNN1A
Hydrochloric Acid SCHEMBL19348118 0.91 SCNN1A (0.56) SCNN1A
SCHEMBL2054438 0.91 SCNN1A (0.54) SCNN1A
SCHEMBL13907673 0.91 SCNN1A (0.54) SCNN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431579-B2 Capped pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. (US) 2013-04-30 US disclosed
US-8314105-B2 Methods of reducing risk of infection from pathogens PARION SCIENCES, INC. (US) 2012-11-20 US disclosed
US-8314105-B2 Methods of reducing risk of infection from pathogens PARION SCIENCES, INC. (US) 2012-11-20 US disclosed
US-8288391-B2 Epithelial Sodium Channel and Acid Sensitive Ion Channel modulators; blocking or enhancing salt and sour tastes; additives in chocolate, ice cream, beverages, candies, or pet foods; side effect reduction PARION SCIENCES, INC. (US) 2012-10-16 US disclosed
US-8288391-B2 Epithelial Sodium Channel and Acid Sensitive Ion Channel modulators; blocking or enhancing salt and sour tastes; additives in chocolate, ice cream, beverages, candies, or pet foods; side effect reduction PARION SCIENCES, INC. (US) 2012-10-16 US disclosed
US-20120165342-A1 Methods of Reducing Risk of Infection from Pathogens PARION SCIENCES, INC. (US) 2012-06-28 US disclosed
US-20120165342-A1 Methods of Reducing Risk of Infection from Pathogens PARION SCIENCES, INC. (US) 2012-06-28 US disclosed
US-20110144338-A1 METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS PARION SCIENCES, INC. (US) 2011-06-16 US disclosed
US-20110144338-A1 METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS PARION SCIENCES, INC. (US) 2011-06-16 US disclosed
US-20110046158-A1 CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2011-02-24 US disclosed
US-20070265280-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2007-11-15 US disclosed
US-7247636-B2 Phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-24 US disclosed
US-7247636-B2 Phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-24 US disclosed
US-7247637-B2 Capped pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-24 US disclosed
US-7241766-B2 Methods of using phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-10 US disclosed
US-7241766-B2 Methods of using phenolic guanidine sodium channel blockers PARION SCIENCES, INC. (US) 2007-07-10 US disclosed
US-7192959-B2 Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis PARION SCIENCES, INC. (US) 2007-03-20 US disclosed
US-7192959-B2 Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis PARION SCIENCES, INC. (US) 2007-03-20 US disclosed
US-7192958-B2 Sodium channel blockers PARION SCIENCES, INC. (US) 2007-03-20 US disclosed
US-7192958-B2 Sodium channel blockers PARION SCIENCES, INC. (US) 2007-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046158-A1 CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS CACNA1B, CACNA1C, HCN4 SCNN1A 65/4885
US-20120165342-A1 Methods of Reducing Risk of Infection from Pathogens KCNN3, KCNN1, KCNN2 SCNN1A 14/4885
US-20110144338-A1 METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS KCNN3, KCNN1, KCNN2 SCNN1A 14/4885
US-20070265280-A1 METHODS OF USING SODIUM CHANNEL BLOCKERS SCN1B, KCNN3, SCN2B SCNN1A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.